Inhalation Drug Delivery Patents: Who Leads, Filing Trends 2026
- Filing has cooled since its 2022 peak. 108 families in 2022 against 76 in 2017 and just 16 in the most recent partial year — a plateau, not a runaway market.
- Medicinal formulation claims dominate the IPC mix. A61K appears in 1,567 records versus 1,235 for A61M devices, meaning formulation chemistry is more contested ground than hardware.
- Ownership is fragmented with thin collaboration. Only 10 co-assignee pairs surface across the corpus, and recent-year momentum at the most active filers is flat or negative.
Filing growth compares 2021 (39 records) with 2024 (81) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 2,362 records in scope (CR5), not by the ranked leaders only.
What this patent set covers
This landscape tracks patent families at the intersection of inhalation drug delivery, dry powder inhalers and pulmonary delivery, filtered to documents whose title, abstract or claims discuss aerodynamic particle size, fine particle fraction, carrier lactose, device resistance or moisture protection. The IPC filter (A61K9, A61M15, A61K47) keeps the set anchored to formulation and device claims rather than the broader respiratory therapeutics literature. Coverage runs from 2015 through the third quarter of 2026.
Across 2,362 families, filing volume rose gradually from 2017 into a 2022 peak before easing off. Because publication typically lags filing by around eighteen months, the last one to two years in any chart will understate true activity — read the tail as a floor, not a ceiling.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology mix
Two views matter here: how filing volume has moved year over year, and which IPC subclasses carry the claim density. Together they show a field that grew steadily, plateaued, and is now concentrated in formulation chemistry more than in device engineering.
A 2022 peak, not a growth curve
Annual filings climbed from 76 in 2017 to a peak of 108 in 2022, then declined toward 16 in the latest partial year. The midpoint sitting at the peak year signals a market that has plateaued rather than one still accelerating — treat any post-2022 dip with the publication-lag caveat in mind before reading it as a real slowdown.
Formulation claims outweigh device claims
A61K medicinal preparations account for 1,567 records, ahead of A61M delivery devices at 1,235 and A61P therapeutic activity at 595. Smaller but present classes — A61L sterilising, A61J containers, B65D/B65B packaging, C07K peptides — show that packaging integrity and biologic-compatible formulation are active but secondary fronts.
Shares are the percentage of the 2,362 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Inhalation and Pulmonary Drug Delivery with Eureka
This page is one run against one query. Ask Eureka your own question about inhalation and pulmonary drug delivery and every answer comes back with the patent numbers behind it.
Try EurekaThe documents setting the citation baseline
Powders for use in a dry powder inhaler (US20030186843A1, Vectura)
A powder for use in a dry powder inhaler comprises an active material and an indicator material that is capable of indicating to a patient that a dose of the active material has been administered. The powder for use in an inhaler device and/or an inhaler device containing the powder may be such that a fine particle fraction of at least 35% is generated.Filed by Vectura Limited, published 2003-10-02.
View full filing| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO1999016419A1 | Perforated microparticles and methods of use | 611 |
| 2 | US20090110679A1 | Methods and compositions for pulmonary administration of a TNFa inhibitor | 285 |
| 3 | US6651655B1 | Inhaled vaccines | 260 |
| 4 | US6284282B1 | Method of spray freeze drying proteins for pharmaceutical administration | 251 |
| 5 | US6613308B2 | Pulmonary delivery in treating disorders of the central nervous system | 249 |
| 6 | US20020058009A1 | Pulmonary delivery in treating disorders of the central nervous system | 224 |
| 7 | US20070235029A1 | Dry powder inhaler | 208 |
| 8 | US6060069A | Pulmonary delivery of pharmaceuticals | 200 |
| 9 | US20090241949A1 | Dry powder inhalation system | 188 |
| 10 | US6889690B2 | Dry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and … | 186 |
Citation counts favour older filings that have had more time to accumulate references within this searched corpus; treat them as markers of influence on the field's vocabulary, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
The trend and IPC data point to a field where the easy formulation claims were staked out years ago, device engineering is comparatively less crowded, and jurisdictional choices still matter.
Volume has plateaued since 2022
The rise from 76 filings in 2017 to a 108-filing peak in 2022 was gradual, and the drop-off since is partly a publication-lag artefact. Even allowing for that lag, this is a mature filing curve rather than an emerging one.
Formulation chemistry is the denser prior art
More records sit under A61K medicinal preparations than under A61M delivery devices, suggesting that carrier, excipient and particle-engineering claims face heavier crowding than mechanical device claims.
US and EPO dominate, but the tail is long
United States filings lead at 498, with Europe at 343 and WIPO PCT entries at 249. Australia, Canada and Israel each carry meaningful volume, which matters for freedom-to-operate work outside the largest two markets.
Ownership is fragmented, not networked
Only ten co-assignee pairs appear in the dataset, and the strongest of them involve single-digit shared filings. Recent-year momentum among the most visible assignees is flat or falling, which points to individual ownership of narrow claim sets rather than joint platforms.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to inhalation and pulmonary drug delivery, with the prior art for and against each one.
Who holds the ground, and where it is thin
Recent-year filing counts at the most visible assignees are flat or in decline, which is consistent with a plateaued field rather than one being actively contested by new entrants. That leaves several technically specific sub-areas comparatively under-claimed.
Even the leaders are pulling back
The assignee with the highest recent-year count still shows a year-over-year decline, and several other historically active filers show zero filings in the latest year. This is a signal to check whether activity has shifted to trade secret or to adjacent IPC codes rather than to assume the technology is exhausted.
A handful of foundational filings set the vocabulary
The most-cited records date from the late 1990s and early 2000s and cover perforated microparticles, pulmonary protein delivery and inhaled vaccines. New filings in these specific mechanisms will be read against decades of citation history.
Partnerships exist but stay narrow
The strongest co-assignee relationship in the dataset tops out at eight shared filings, and the next strongest pairs sit at seven. These look like specific licensing or contract-development arrangements rather than broad platform alliances.
| Assignee | Recent year | YoY |
|---|---|---|
| Meikang Inc. | 2 | -60% |
| Vectura Limited | 0 | — |
| Civitas Therapeutics | 0 | — |
| MicroDose Corp | 0 | — |
| Medrio S.p.A. | 0 | — |
| Chiesi Farmaceutici S.p.A. | 0 | -100% |
| AstraZeneca LLC | 0 | — |
| Advanced Inhalation Research, Inc. | 0 | — |
Where to take this analysis
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, licensing or new filing strategy.
Map claims against the device-side white space
With A61M device records trailing A61K formulation records by a meaningful margin, a claim-by-claim review of resistance-tuning and dose-indicator mechanisms is likely to surface more open ground than another formulation filing.
Explore device claims in EurekaCheck jurisdiction coverage beyond the US and EPO
With Australia, Canada and Israel each carrying meaningful filing volume, a freedom-to-operate search limited to US and PCT records will miss real prior art in those offices.
Run a jurisdiction sweep in EurekaVerify whether inactive assignees have moved elsewhere
Several previously active assignees show zero filings in the latest year. Before treating that as market exit, check adjacent IPC classes and trade secret filings for the same entities.
Track assignee activity in EurekaCommon questions on inhalation and pulmonary delivery patents
This dataset identifies 2,362 patent families filed between 2015 and mid-2026 that combine inhalation drug delivery, dry powder inhaler or pulmonary delivery language with technical detail on aerodynamic particle size, fine particle fraction, carrier lactose, device resistance or moisture protection. That is a filtered figure, not a count of every respiratory patent; broader searches on inhalation therapeutics alone would return a larger set. The IPC restriction to A61K9, A61M15 and A61K47 keeps the scope on formulation and device claims specifically.
Filing volume rose from 76 families in 2017 to a peak of 108 in 2022, then declined toward 16 in the latest partial year. Because publication lags filing by roughly eighteen months, the most recent year always understates true activity, but even accounting for that lag the trend looks like a plateau rather than continued growth. Anyone using this data for a go/no-go decision should treat 2022 as the high-water mark so far, not assume a rebound is coming.
Formulation claims are the denser prior art: A61K medicinal preparations account for 1,567 records against 1,235 for A61M delivery devices in this corpus. That does not mean device engineering is untouched, but it does mean carrier, excipient and particle-engineering claims face more competing prior art than mechanical inhaler design. A new filer with a genuine device-side innovation may find more open claim space than one filing on formulation alone.
US20030186843A1 describes a powder for use in a dry powder inhaler that combines an active material with an indicator material signalling to the patient that a dose has been administered, with the powder engineered to generate a fine particle fraction of at least 35%. It is a representative filing in this landscape rather than the single most-cited one, but it illustrates the dose-indicator and fine-particle-fraction claim style that recurs across the corpus. Anyone designing a competing dry powder formulation with dose-confirmation features should review its claim scope directly rather than relying on the abstract alone.
The corpus shows filing concentrated among a handful of specialist pharmaceutical and device firms, several of which show flat or declining recent-year filing counts rather than continued acceleration. Co-assignee relationships are limited to ten pairs across the whole dataset, with the strongest topping out at eight shared filings, which points to fragmented ownership rather than a small number of dominant platform holders. That fragmentation is itself useful signal: it suggests licensing-in from a specific patent holder may be more tractable than trying to out-file an entrenched leader.
Research Inhalation and Pulmonary Drug Delivery in depth with Eureka
Go past this page: query the whole inhalation and pulmonary drug delivery corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.